Exhibit 12

State of California ex. rel. Ven-A-Care of the Florida Keys, Inc. v. Abbott Laboratories, Inc., et al.

Exhibit to the Declaration of Steven U. Ross in Support of Plaintiffs' Opposition to Sandoz, Inc.'s Motion for Summary Judgment

March 19, 2008

Sacramento, CA

Page 1 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MASSACHUSETTS ----X IN RE: PHARMACEUTICAL) MDL NO. 1456 INDUSTRY AVERAGE WHOLESALE) CIVIL ACTION:) 01-CV-12257-PBS PRICE LITIGATION ----X THIS DOCUMENT RELATES TO:) Judge Patti B. Saris U.S. ex rel. Ven-A-Care of) the Florida Keys, Inc. v.) Magistrate Judge Abbott Laboratories, Inc.,) Marianne B. Bowler et al. Case No. 06-CV-11337-PBS ----X --000--WEDNESDAY, MARCH 19, 2008 --000--VIDEOTAPED DEPOSITION OF JAMES KEVIN GOROSPE Reported By: JOANIE MURAKAMI, CSR No. 5199 Registered Merit Reporter Certified Realtime Reporter

March 19, 2008

Sacramento, CA

```
Page 373
 1
     you the value of the supplemental rebate.
          Q.
               Okay.
                     Understood. Okay. Now, in the
     context of the supplemental rebates that are
     based on AMP, I just wanted to ask you a couple
 5
     follow-up questions about that.
 6
               Based on your knowledge and experience,
 7
     the AMPs that are reported by manufacturers, are
     they always reliable?
               MR. COLE: Object to the form.
10
               THE WITNESS: What do you mean by
11
     "reliable"?
12
     BY MR. GOBENA:
13
               Do they sometimes change?
          0.
          Α.
               Yes.
15
               And in fact, isn't it true that
16
     sometimes manufacturers will restate AMPs that
17
     they had previously reported; isn't that true?
18
          Α.
               Yes.
19
               And sometimes they'll dispute -- there
20
     will be a dispute between Medi-Cal and a
21
     manufacturer about the reported AMP; isn't that
22
     correct?
```

March 19, 2008

Sacramento, CA

```
Page 374
          Α.
               No.
                Okay. What have I gotten wrong about
          Q.
 3
     that, my characterization after dispute?
          Α.
                Disputes generally are over the
 5
     rebates.
          0.
                I see.
 7
               And not the reported AMP.
          Α.
                       But it's not unusual for there
          0.
                Okay.
     to be restatements of previously reported AMPs;
10
     isn't that correct?
11
                That's correct.
12
               Okay. So -- and based on your
          Q.
13
     knowledge and experience, how often do
14
     manufacturers tend to restate their AMPs?
15
                I don't know a frequency specifically.
          Α.
16
               Does it depend on the manufacturer?
17
                Some manufacturers have -- seem to have
18
     more changes than others but I couldn't
19
     characterize any one particular manufacturer and
20
     percentage of changes.
21
                So you can't give us any specific
22
     knowledge on any restatements of AMP done by
```

March 19, 2008

Sacramento, CA

```
Page 375
     Abbott for any of its product, correct?
 2
          Α.
               No.
 3
               But given the fact that AMPs can be
     restated -- strike that.
 5
               Given the fact that AMPs can be
     restated from time to time, isn't it true that an
 7
     AMP that is provided by a manufacturer at any
     given time may not be necessarily reliable?
               MR. COLE: Object to the form.
10
               THE WITNESS:
                              That's correct.
11
               MR. GOBENA:
                             All right. Those are all
12
     the questions I have for right now, and I'll pass
13
     the witness back to Jeremy if he has some
14
     additional questions on the US case.
15
16
                     FURTHER EXAMINATION
17
     BY MR. COLE:
18
               Dr. Gorospe, very quickly, Mr. Gobena
          0.
19
     asked you whether it was ever -- I believe he
20
     asked you whether it was ever Medi-Cal's policy
21
     to overpay for drug ingredient costs.
22
               Do you remember that question?
```